Joseph Pantginis has joined Rodman & Renshaw in equity research as a managing director covering biotechnology.Read More
odman & Renshaw initiated coverage of Catalyst Biosciences (NASDAQ:CLIO) with a “buy” rating and a 12-month price target of $3.50. The stock closed at $1.25 on Wednesday.
Using its proprietary protease platform, Catalyst Biosciences is advancing its lead hemostasis programs for hemophilia A and B, as well as its anti- complement programs, which could be applicable across various other disorders, including delayed graft function in kidney transplantation and age-related macular degeneration, a chronic eye disease.Read More
Rodman & Renshaw has launched coverage of Bio-Path Holdings (NASDAQ:BPTH) with a “buy” rating and a 12-month price target of $5. The stock closed at $2.76 on Monday.
“In our view, Bio-Path’s unique liposomal delivery of antisense DNA has the potential to significantly improve treatment outcomes in elderly patients (≥60 years) with acute myeloid leukemia (AML),” writes analyst Raghuram Selvaraju.Read More
Rodman & Renshaw analyst Raghuram Selvaraju has assumed coverage of NephroGenex (NASDAQ:NRX) with a “neutral” rating and without a price target. The stock was quoted at 40 cents Friday afternoon.
The board of NephroGenex decided in late February 2016 to pause the oral Pyridorin pivotal program in diabetic nephropathy, to effect a restructuring of the company’s operations and implement a strategic transaction.Read More
Rodman & Renshaw has launched coverage of Nanosphere (NASDAQ:NSPH) with a “buy” rating and price target of $2. The stock closed at 87 cents on Monday.
“In our view, the company’s Verigene system and test panels are differentiated from competing systems in that it is based on the gold nanoparticle technology for direct detection of pathogens without the use of PCR, and it offers test and pricing flexibility while having multiplex capacity (identifying multiple targets in one test),” writes analyst Yi Chen.Read More
Rodman & Renshaw has started coverage of BioSpecifics Technologies (NASDAQ:BSTC) with a “buy” rating and 12-month price target of $60. The stock closed at $35.97 on Monday.
The company’s sole product is the collagenase clostridium histolyticum (CCH) for injection, which is approved for the treatment of Dupuytren’s contracture and Peyronie’s disease both in the U.S. and Europe. CCH also recently received regulatory approval in Japan for Dupuytren’s contracture and in Switzerland for Peyronie’s disease.Read More
Rodman & Renshaw has launched coverage of EyeGate Pharmaceuticals (NASDAQ:EYEG) with a “buy’ rating and a 12-month price target of $10. The stock closed at $1.70 on Friday.
"In our view, the company’s EGP-437 combination product is differentiated from eye drops and intraocular injections in that it is non-invasive and solves patient non-compliance and safety issues that currently plague conventional ophthalmic drug delivery methods,” writes analyst Yi Chen.Read More
Rodman & Renshaw has initiated coverage of VolitionRx (NASDAQ:VNRX) with a “buy” rating and a 12-month price target of $12. The stock closed at $3.77 on Friday.
“In our view, the company’s blood-based NuQ screening test for colorectal cancer, based on its proprietary nucleosomics epigenetic biomarker platform, is differentiated from traditional detection methods and other competing blood-based technologies in terms of accuracy, convenience and pricing,” writes analyst Yi Chen.Read More